1Robert Wood Johnson University Hospital, New Brunswick, NJ, USA
2Weill Cornell Medical College, New York, NY, USA
3La Policia, Bogota, Colombia
4Borland-Groover, Jacksonville, FL, USA
5Juarez Hospital, Mexico City, Mexico
6Belo Horizonte Hospital, Belo Horizonte, Brazil
7Hospital Escuela Dr. Ramon Madariaga, Posadas, Argentina
8Gemelli University Hospital, Roma, Italy
9Santander Hospital, Reynosa, Mexico
10San Ignacio University Hospital, Bogota, Columbia
11Gastromedica Clinic, Managua, Nicaragua
12Gastrointestinal Endoscopy Unit, University of Sao Paulo, Sao Paulo, Brazil
13Instituto Ecuatoriano de Enfermedades Digestivas, Guayaquil, Ecuador
Copyright © 2021 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest: Amy Tyberg has done consulting work for Nine Point Medical, Endo Gastric Solutions, and Obalon Therapeutics. She is a board director at the Therapeutic EUS Society Inc. Michel Kahaleh has done consulting work for Boston Scientific, Interscope Med, Obalon Therapeutics, and Abbvie. He has received research grants from Boston Scientific, Conmed, Pinnacle, Cook, Gore, Merit, and Olympus. He is the CEO of Innovative Digestive Health Education & Research Inc. and the Therapeutic EUS Society Inc. M. Kahaleh has received grant support from Boston Scientific, Fujinon, W.L. Gore, Mauna Kea, Apollo Endosurgery, Cook Endoscopy, ASPIRE Bariatrics, GI Dynamics, Nine Point Medical, Merit Medical, Interscope Med, Olympus, ERBE, and MI Tech. He is a consultant for Boston Scientific, Concordia Laboratories Inc., ABBvie, and Mauna Kea Tech. None of the funding was related to this study. Monica Gaidhane has done consulting work for Interscope Med. She is the COO of Innovative Digestive Health Education & Research Inc. and the Therapeutic EUS Society Inc. The other authors have no potential conflicts of interest.
Funding
None.
N=125 | |
---|---|
Male:Female | 65:60 |
Age (years) | |
Mean (SD) | 59.14 (12.48) |
Achalasia Type | 122 |
• Type I | 9 |
• Type II | 80 |
• Type III | 33 |
• Jackhammer esophagus | 2 |
• Nutcracker esophagus | 1 |
Chagas disease (%) | 38 (30.4%) |
Prior treatments | |
• Heller myotomy (%) | 18 (14.4%) |
• Pneumatic dilation (%) | 17 (13.6%) |
• Botulinum toxin (%) | 6 (4.8%) |
No prior treatments | 84 (67.2%) |
Pre-procedure | |
Mean Eckardt score (SD) | 6.79 (2.05) |
Mean LES pressure (mmHg) | 29.04 |
Orientation | |
Anterior:Posterior | 26:99 |
Device for closure | |
Clips:Overstitch suture | 120:5 |
Post-procedure (3 months) | |
Mean Eckardt score (SD) | 1.87 (2.15) |
Mean LES pressure (mmHg) | 22.56 |
Technical success | 117 (93.5%) |
Clinical success | 111 (88.8%) |
Complications | |
• Bleeding | 4 |
• Pneumothorax | 4 |
• Mucosal perforation | 13 |
• Mediastinitis | 2 |
• Leak | 4 |
Interventions for complications | |
• Hemoclips (mucosal perforations) | 12 |
• Overscope clips (mucosal perforations) | 1 |
• Needle decompression (pneumothorax) | 1 |
• Chest tubes (pneumothorax) | 3 |
• Coagulation (bleeding) | 1 |
• Reclips (leaks) | 4 |
• Antibiotics (mediastinitis) | 2 |
Procedure time (minutes, SD) | 102.65 (42.48) |
Hospital stay (days, SD) | 1.98 (0.97) |
Follow up duration (months, SD) | 16 (12.89) |
Reinterventions | |
• Heller myotomy | 5 |
• Pneumatic dilation | 8 |
LES, lower esophageal sphincter; SD, standard deviation.